Literature DB >> 1419819

Age-related incidence and other epidemiological aspects of myelodysplastic syndromes.

C Aul1, N Gattermann, W Schneider.   

Abstract

Although most haematologists perceive a rising prevalence and incidence of myelodysplastic syndromes (MDS), reliable epidemiological data on these disorders are largely lacking. The bone marrow register of the University of Düsseldorf allowed us to assess among other epidemiological features the incidence of MDS, which was compared to that of acute myeloid leukaemia (AML). Among a total of 18,416 different patients registered between 1975 and 1990, 584 cases of MDS (3.2%) and 506 cases of AML (2.8%) were identified. Over the study period, the percentage of newly diagnosed MDS rose from 1.3% to 4.5%, while there was no upward trend for AML. Among all patients undergoing bone marrow biopsy, the proportion of those over 60 years of age increased from 41.9% in 1975 to 54.1% in 1990. We found a strong correlation between the proportion of elderly patients and the relative frequency of MDS diagnoses. Thirty-one patients (5.3%) were classified as a secondary MDS because of previous treatment with cytotoxic chemotherapy and/or irradiation for a variety of malignancies. Twelve patients were identified in whom occupational exposure to organic solvents could not be ruled out. For calculating age-specific incidence rates, the analysis was confined to the town district of Düsseldorf (575,000 inhabitants), because exact demographical data were available for this population. In the last quinquennium of the study period (1986-90), myelodysplastic syndromes were more frequent than AML in the age group 50-70 years (4.9 v 1.8/100,000/year). In patients over 70, the incidence of MDS was more than 3 times that of AML (22.8 v 6.7/100,000). In this group, men had a higher incidence of MDS (33.9/100,000) than women (18/100,000). Crude annual incidence (all age groups) was also higher for MDS (4.1/100,000) than for AML (2.1/100,000) in recent years. We conclude that MDS are relatively common haematological neoplasias. The rising incidence in recent years is probably not due to changes in aetiological factors, but may reflect increased awareness on the part of physicians and extended use of diagnostic procedures in elderly patients.

Entities:  

Mesh:

Year:  1992        PMID: 1419819     DOI: 10.1111/j.1365-2141.1992.tb06430.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  36 in total

1.  Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors.

Authors:  Stefani Parmentier; Johannes Schetelig; Kerstin Lorenz; Michael Kramer; Robin Ireland; Ulrich Schuler; Rainer Ordemann; Gabi Rall; Markus Schaich; Martin Bornhäuser; Gerhard Ehninger; Frank Kroschinsky
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

2.  Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease.

Authors:  Manuel Aivado; Dimitrios Spentzos; Ulrich Germing; Gil Alterovitz; Xiao-Ying Meng; Franck Grall; Aristoteles A N Giagounidis; Giannoula Klement; Ulrich Steidl; Hasan H Otu; Akos Czibere; Wolf C Prall; Christof Iking-Konert; Michelle Shayne; Marco F Ramoni; Norbert Gattermann; Rainer Haas; Constantine S Mitsiades; Eric T Fung; Towia A Libermann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-12       Impact factor: 11.205

3.  Features of Japanese patients with myelodysplastic syndrome in an aging population of Sado Island.

Authors:  Kumiko Yagisawa; Kiyoshi Okazuka; Ken Toba; Masaru Urushiyama; Takashi Kuroha; Noriko Izumi; Yasuhiko Sibasaki; Masutaka Higashimura; Toshio Yano; Akihito Momoi; Akira Hattori; Ken Momotsu; Yoshifusa Aizawa
Journal:  Int J Hematol       Date:  2012-02-24       Impact factor: 2.490

4.  Myelodysplastic syndromes: challenges to improving patient and caregiver satisfaction.

Authors:  B Douglas Smith
Journal:  Am J Med       Date:  2012-07       Impact factor: 4.965

Review 5.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.

Authors:  R Tehranchi
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

6.  A Prospective, Cross Sectional Study of PNH Clone in MDS Patients Using High Sensitivity Flowcytometry: A Single Center Experience.

Authors:  Faran Naim; Amrita Saraf; Jasmita Dass; Vandana Arya; Sabina Langer; Nitin Gupta; Ajay Sharma; Jyoti Kotwal
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-24       Impact factor: 0.900

7.  Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys.

Authors:  Mikkael A Sekeres; W Marieke Schoonen; Hagop Kantarjian; Alan List; Jon Fryzek; Ronald Paquette; Jaroslaw P Maciejewski
Journal:  J Natl Cancer Inst       Date:  2008-10-28       Impact factor: 13.506

8.  Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies.

Authors:  Charikleia Kelaidi; Aspasia Stamatoullas; Odile Beyne-Rauzy; Emmanuel Raffoux; Bruno Quesnel; Agnes Guerci; François Dreyfus; Sabine Brechignac; Christian Berthou; Thomas Prebet; Yosr Hicheri; Maya Hacini; Jacques Delaunay; Marie-Pierre Gourin; Jean-Marie Camo; Hacene Zerazhi; Anne-Laure Taksin; Laurence Legros; Bachra Choufi; Pierre Fenaux
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

9.  Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Britta Will; Masahiro Kawahara; Julia P Luciano; Ingmar Bruns; Samir Parekh; Connie L Erickson-Miller; Manuel A Aivado; Amit Verma; Ulrich Steidl
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

10.  Successful replacement of aortic root with valve-sparing technique and proximal arch in a patient with myelodysplastic syndrome.

Authors:  Tomomi Hasegawa; Takuro Tsukube; Tomonori Higuma; Yutaka Okita
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2003-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.